Incrementality measures the incremental effect or ‘ lift’ the
advertising effort brings above the baseline conversion rate for a
target population. Advertisers tend to already know who are most
inclined to buy their product. With incrementality, the question
becomes, what is the effect of the ads on that consumer above and beyond
their purchase level without the advertising.
This term has been around for ages but now, as the media industry
expands its data capabilities, it has become a hot topic. The
proliferation of platforms and the expansion of all types of available
datasets leave us with an embarrassment of riches … and a challenge.
Which platform really added value and which dataset is best to measure that incrementality.
At a recent ARF meeting,
ARF Leadership Lab speaker Rick Bruner, CEO/Co-Founder of Central
Control and US Vice Chair of I-COM hosted a panel of media executives.
To Bruner, incrementality “is the latest, and certainly greatest,
buzzword in the history of advertising.” To research experts it involves
randomized controlled trials (RCT) that connotes Return on Investment
(ROI), by using trial and error. “That’s the formula for advertising
success,” he explained.
For
brands such as Walmart, incrementality is a must-know, as noted by the
Director of Product at WalmartLabs, Vadim Tsemekhman, who stated, “Our
Top Priority: Focus on finding ways to conduct scaled randomized
controlled testing across every marketing channel.”
But RCT demands a degree of experimental risk where time and money
are invested in a test that may not pay off. One way of conducting RCT
experiments is through the use of “ghost ads” – not exposing likely consumers to an ad and then comparing their behavior to a group of those who were
exposed. It is time consuming but will lead to a greater understanding
of which platforms are really moving the needle for a brand campaign.
“My prediction is that, come Monday morning, everyone who reports
‘lift’ for advertising effect based on something other than RCT is
suddenly going to be in the market for real RCT,” concluded Bruner.
This article first appeared in Cynopsis.
No comments:
Post a Comment